Health ❯ Healthcare ❯ Cancer Treatment
Checkpoint Inhibitors Pembrolizumab Bispecific Antibodies Personalized Medicine Immune Checkpoint Inhibitors Epcoritamab mRNA Vaccines Vaccine Development Patient Care Combination Therapy Tumor Microenvironment Targeted Therapy Support Systems Genetic Therapy Combination Therapies Cancer Vaccines PD-L1 Inhibitors Microbiome Enhancement Ipilimumab and Nivolumab PD-L1 Targeting AI in Cancer Treatment Therapeutic Antibodies PD-1 Neutrophil-Targeted Therapies Pembrolizumab and Decitabine IL-6 Inhibitors Microbiome Effects KRAS Mutations Microbiota-based Therapies Therapeutic Strategies FLT3xCD3 Bispecific T Cell Engager Chemoimmunotherapy Regulatory T Cell Therapy Daratumumab Immune Checkpoint Blockade T Cell Therapy PD-1 Inhibition Clinical Research Anti-BCMA Therapy Targeted Therapies Vaccine-Induced Immunity Bone Marrow Antibody Therapies Durvalumab PD-1 Inhibitors Melanoma Early Intervention Immune Evasion T Cell Exhaustion Natural Killer Cells Immunochemotherapy T Cell Immunotherapies Precision Medicine Therapeutic Implications Prostate Cancer Emotional Impact of Illness Effectiveness in Obese Patients Ipilimumab AI in Healthcare Cretostimogene Grenadenorepvec Radiation Therapy Neoantigen Vaccines mRNA-based Therapies Erythropoietin (EPO) Nivolumab
The study tested an ATR inhibitor with Imfinzi in patients whose disease progressed after immunotherapy plus platinum chemotherapy.
